Market Overview

Cerenis Announces Today the Appointment of Barbara Yanni to Its Board of Directors as an Independent Director


Regulatory News:

Cerenis Therapeutics (FR0012616852 – CEREN – PEA PME eligible),
an international biopharmaceutical company dedicated to the discovery
and development of HDL-based innovative therapies for treating
cardiovascular, metabolic diseases, and new HDL-based vectors for the
targeted drug delivery in the oncology field announces today the
appointment of Barbara Yanni to its Board of Directors as an Independent

Jean-Louis Dasseux, founder and CEO of Cerenis,
said: "We are proud to welcome Barbara Yanni to Cerenis' Board
of Directors. This is a unique opportunity for us, as Barbara is highly
regarded in the pharmaceutical industry as a business and financial
expert with deep experience as a senior business development executive.
Barbara retired from Merck & Co., Inc. in 2014 after 12 years as Merck's
Vice President and Chief Licensing Officer.
While at Merck,
Barbara and her team successfully structured and negotiated agreements
to acquire rights to over 150 compounds, programs and technologies to
enhance Merck's pipeline.

Her endeavors also allowed Merck to be recognized as the "best
biopharma partner". Without any doubt we will greatly benefit from her
superb interpersonal skills and background to help Cerenis in future
strategy and deal negotiations as we better understand large and small
potential partners

Barbara Yanni, JD, MA, BA - Independent Administrator

Former Vice President and Chief Licensing Officer at Merck & Co., Inc.

Barbara is currently an Independent Director of three other
clinical-stage biotech companies: Trevena Inc. (NASDAQ:TRVN), Vaccinex,
Inc. and Symic Bio. She has more than thirty years of experience in
pharma and biotechnology. As Chief Licensing Officer at Merck & Co.,
Inc. she has built strong relationships within the pharmaceutical,
biotech and venture community. She oversaw successful strategic
collaborations for 33 clinical and/or commercial compounds, 13
preclinical compounds and more than 100 compounds at the discovery,
formulation or research technology stage. Prior to her leadership roles
in business development at Merck, Barbara conducted financial analyses
of business development opportunities and employee benefits and devised
and implemented strategies to minimize Merck's corporate taxes.

Barbara Yanni holds an AB in Physics from Wellesley College, an LLM in
Taxation from New York University and a JD from Stanford Law School.


CERENIS Therapeutics is an international biopharmaceutical company
dedicated to the discovery and development of innovative lipid
metabolism therapies for the treatment of cardiovascular, metabolic
diseases, and HDL platform technologies. HDL is the primary mediator of
the reverse lipid transport, or RLT, the only natural pathway by which
excess lipids are removed from arteries and transported to the liver for
elimination from the body. In addition to advancing HDL technologies for
drug delivery, CERENIS is developing a portfolio of lipid metabolism
therapies, including HDL mimetics for patients with genetic HDL
deficiency, as well as drugs which increase HDL for patients with a low
number of HDL particles to treat atherosclerosis and associated
metabolic diseases including Non-Alcoholic Fatty Liver Disease (NAFLD)
and Non-Alcoholic Steato-Hepatitis (NASH). Leveraging its expertise,
Cerenis is developing the first platform for the targeted drug delivery
by HDL dedicated to the field of oncology (immuno-oncology and

CERENIS is well positioned to become one of the leaders in the HDL
therapeutic market, with a broad portfolio of programs in development.

About Targeted HDL Drug Delivery

HDL particles, loaded with an active agent, hold the promise to target
and selectively kill malignant cells while sparing healthy ones. A wide
variety of drugs can be embedded in these particles targeting markers
specific to cancer cells and bring these potent drugs to their intended
site of action, with lowered systemic toxicity. Cerenis intends to
develop the first HDL-based targeting drug delivery platform dedicated
to the oncology market, including immuno-oncology and chemotherapy.

Financial Calendar

2018 Half year Results: September 11th, 2018

View Comments and Join the Discussion!